Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2022

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System ("CNS") disorders by leveraging its...

Related Keywords

Mahesh Patel ,George Nomikos ,Spyros Papapetropoulos ,Prnewswire Lipocine Inc ,Lipocine Inc ,Nasdaq ,Central Nervous System ,Lead Director ,Chief Medical ,Months Ended ,Private Securities Litigation Reform Act ,Consolidated Statements ,Months Ended September ,